Heart Failure

A 3-pound weight gain overnight doesn't look dramatic on a scale — but in heart failure, it's a clinical alarm that demands action before symptoms even appear.

Daily self-monitoring is the frontline defense against heart failure exacerbation. The cornerstone is daily weight: same scale, same time (morning), after voiding, before eating, in similar clothing. A gain of 2 lbs in 24 hours or 3-5 lbs in one week signals fluid retention and warrants immediate provider notification — this often precedes visible edema or dyspnea by 1-2 days. Weight is more sensitive than symptom tracking alone because fluid accumulates internally before the patient feels it. Beyond weight, daily monitoring includes assessing for increasing dyspnea, orthopnea (tracking how many pillows needed), peripheral edema (checking ankles bilaterally at the same time of day), fatigue with usual activities, and abdominal bloating. Intake and output tracking helps correlate fluid balance with weight trends. Patients should keep a written log to share with providers, noting weight, symptoms, and any dietary indiscretions. The nurse's role centers on teaching the patient to recognize these patterns and act on thresholds — not just record numbers passively. Reinforce that monitoring is a daily habit, not something to do only when feeling worse.

Key Distinctions

Don't confuse daily monitoring (self-assessment at home) with labs and diagnostics (BNP, echocardiography) — monitoring catches trends between clinic visits while diagnostics confirm severity. Students mix up the 2-lb/day threshold with the 3-5 lb/week threshold; both are reportable but represent different timeframes. Weight gain from fluid retention is rapid (days), whereas weight gain from caloric excess is gradual (weeks) — speed of change is the distinguishing factor.

Clinical Pearl

Morning weight is the cheapest, fastest heart failure test there is. Two pounds in a day means liters, not lunch — call the provider.

Lifestyle & Diet

Heart failure management between clinic visits depends on non-pharmacologic interventions the nurse teaches and reinforces. Sodium restriction is the cornerstone: the standard recommendation is less than 2,000 mg (2 g) per day for most HF patients. Teach the patient to read nutrition labels, avoid canned/processed foods, and never add salt at the table. Fluid restriction typically ranges from 1.5 to 2 liters per day and is prescribed when the patient has persistent fluid overload or hyponatremia. The patient should spread fluid intake across the day and count ice chips, gelatin, and soup as fluid. Activity should follow a graduated approach — not bed rest. Regular low-intensity exercise (walking, cardiac rehab) improves functional capacity and reduces hospitalizations. Alcohol is restricted because it is a direct myocardial depressant; even moderate intake worsens systolic function. Smoking cessation is essential because nicotine increases afterload and heart rate. Small, frequent meals reduce cardiac workload compared to large meals that divert blood flow to the gut. These modifications work synergistically with the medication regimen but are the patient's responsibility to maintain daily.

Key Distinctions

Don't confuse sodium restriction (less than 2 g/day) with a no-salt diet — patients still need some sodium and should avoid salt substitutes containing potassium if they're on ACE inhibitors or potassium-sparing diuretics. Students often think fluid restriction is universal in HF, but it's specifically indicated for refractory volume overload or dilutional hyponatremia, not every HF patient. Activity restriction (bed rest) is outdated — current guidelines promote structured exercise.

Clinical Pearl

2-2-6: less than 2 g sodium, up to 2 L fluid, and call the provider for a gain of more than 2 lbs overnight or 6 lbs in a week.

HF Labs & Diagnostics

B-type natriuretic peptide (BNP) is the cornerstone lab for heart failure evaluation. Ventricular myocytes release BNP when wall stress increases from volume overload. A BNP below 100 pg/mL makes HF unlikely; above 400 pg/mL strongly supports the diagnosis. NT-proBNP uses different cutoffs — below 300 pg/mL helps rule out HF, while rule-in thresholds are age-stratified: >450 for age <50, >900 for age 50–75, and >1800 for age 75+. Obesity falsely lowers BNP, so a normal level in an obese patient doesn't exclude HF. Renal failure falsely elevates it. Beyond BNP, echocardiography is the definitive diagnostic — it quantifies ejection fraction (EF), distinguishes systolic (EF ≤40%) from diastolic failure (EF ≥50%, preserved), and identifies valvular or structural causes. Chest X-ray findings include cardiomegaly, cephalization of pulmonary vessels, Kerley B lines, and pleural effusions. Basic metabolic panel matters because electrolyte imbalances (especially potassium, sodium, magnesium) guide medication safety. A low serum sodium (below 135 mEq/L) in HF signals dilutional hyponatremia from fluid overload and indicates worse prognosis.

Key Distinctions

Don't confuse BNP with troponin — BNP reflects ventricular stretch from volume/pressure overload, while troponin indicates myocardial cell death (MI). Students assume a normal BNP always rules out HF, but obesity suppresses BNP release, creating false negatives. Echocardiography determines the type of HF (systolic vs. diastolic); BNP cannot differentiate between them.

Clinical Pearl

Think of BNP as the ventricle's distress call — the more stretched the walls, the louder the signal. But a quiet signal in an obese patient doesn't mean no distress.

HF Medication Regimen

Guideline-directed medical therapy (GDMT) for HFrEF (EF ≤40%) rests on four pillars: ACE inhibitors or ARBs (or sacubitril/valsartan), beta-blockers (carvedilol, metoprolol succinate, bisoprolol), aldosterone antagonists (spironolactone, eplerenone), and SGLT2 inhibitors (dapagliflozin, empagliflozin). ACE inhibitors reduce afterload and block harmful neurohormonal remodeling — monitor for dry cough, hyperkalemia, and angioedema. ARBs substitute when cough is intolerable but never combine with an ACE inhibitor. Sacubitril/valsartan (ARNI) replaces the ACE/ARB and requires a 36-hour washout from any ACE inhibitor to prevent angioedema. Beta-blockers are started at low doses when the patient is euvolemic — never during acute decompensation — and titrated slowly. They reduce mortality by blunting sympathetic overdrive. Spironolactone is potassium-sparing; potassium and creatinine must be monitored closely, especially when combined with ACE inhibitors. Loop diuretics (furosemide) manage volume overload but are symptom relief only — they do not improve survival. Digoxin may be added to reduce hospitalizations but does not reduce mortality.

Key Distinctions

Don't confuse survival drugs (ACE inhibitors, beta-blockers, aldosterone antagonists, SGLT2 inhibitors) with symptom-relief drugs (loop diuretics, digoxin) — the NCLEX tests whether a medication improves mortality or just manages symptoms. Students mix up spironolactone (potassium-sparing, watch for hyperkalemia) with furosemide (potassium-wasting, watch for hypokalemia). Beta-blockers are contraindicated in acute decompensation but are essential in stable chronic HF — the timing of initiation is a classic test trap.

Clinical Pearl

Furosemide makes the patient feel better; ACE inhibitors, beta-blockers, spironolactone, and SGLT2 inhibitors make the patient live longer. The NCLEX loves this distinction.